Antonio Guglietta

Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial

James F. Howard, Vera Bril, Tuan Vu et al. · The Lancet Neurology · 2021 · 587 citations · Full text

Medicine, Generalised Myasthenia Gravis

Neonatal Fc receptor antagonist efgartigimod safely and sustainably reduces IgGs in humans

Peter Ulrichts, Antonio Guglietta, Torsten Dreier et al. · Journal of Clinical Investigation · 2018 · 334 citations · Full text

Randomized phase 2 study of FcRn antagonist efgartigimod in generalized myasthenia gravis

James F. Howard, Vera Bril, Ted M. Burns et al. · Neurology · 2019 · 268 citations · Full text

The correlation between epidermal growth factor levels in saliva and the severity of oral mucositis during oropharyngeal radiation therapy

Joel B. Epstein, Meir Gorsky, Antonio Guglietta et al. · Cancer · 2000 · 137 citations

Synthesis, Structure−Activity Relationships, and in Vivo Evaluations of Substituted Di-<i>tert</i>-butylphenols as a Novel Class of Potent, Selective, and Orally Active Cyclooxygenase-2 Inhibitors. 1. Thiazolone and Oxazolone Series

Yuntao Song, David T. Connor, Robert Doubleday et al. · Journal of Medicinal Chemistry · 1999 · 130 citations · Full text

Pharmaceutical Science, Chemoprevention Strategy, Pharmacotherapy +20